Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

VEGFR Therapy’s Role in Reducing RCC Progression

Curr Med Res Opin; ePub 2018 Feb 1; Tannir, et al

With checkpoint inhibitors emerging as potential treatment approaches for advanced renal cell carcinoma, combining or sequencing them with vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKIs) may reduce or delay disease progression, according to a recent review. Preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. The authors discuss the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.

Citation:

Tannir N, Hammers H, Amin A. Impact of comorbidities on functional recovery from partial nephrectomy. [Published online ahead of print February 1, 2018]. Curr Med Res Opin. doi:10.1080/03007995.2018.1423960.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Must Reads in Renal Cell Carcinoma

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010